Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Boehringer Ingelheim
Harvard Business School
Moodys
AstraZeneca

Last Updated: January 24, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Olmutinib


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Olmutinib?

Olmutinib is an investigational drug.

There have been 7 clinical trials for Olmutinib. The most recent clinical trial was a Phase 2 trial, which was initiated on July 17th 2017.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and [disabled in preview]. The leading clinical trial sponsors are Hanmi Pharmaceutical Company Limited, Boehringer Ingelheim, and Konkuk University Medical Center.

There are twenty-five US patents protecting this investigational drug and two hundred and twenty-six international patents.

Recent Clinical Trials for Olmutinib
TitleSponsorPhase
Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKIHanmi Pharmaceutical Company LimitedPhase 1
Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNAHanmi Pharmaceutical Company LimitedPhase 2
Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNAKonkuk University Medical CenterPhase 2

See all Olmutinib clinical trials

Clinical Trial Summary for Olmutinib

Top disease conditions for Olmutinib
Top clinical trial sponsors for Olmutinib

See all Olmutinib clinical trials

US Patents for Olmutinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Olmutinib ⤷  Sign up for a Free Trial Method for preparing thienopyrimidine compound and intermediates used therein HANMI PHARM. CO., LTD. (Hwaseong-si, KR) ⤷  Sign up for a Free Trial
Olmutinib ⤷  Sign up for a Free Trial Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN) ⤷  Sign up for a Free Trial
Olmutinib ⤷  Sign up for a Free Trial Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors Felicitex Therapeutics, Inc. (Natick, MA) ⤷  Sign up for a Free Trial
Olmutinib ⤷  Sign up for a Free Trial Process for preparing thienopyrimidine compound and intermediates used therein HANMI PHARM. CO., LTD. (Hwaseongi-si, KR) ⤷  Sign up for a Free Trial
Olmutinib ⤷  Sign up for a Free Trial Bifunctional molecules for degradation of EGFR and methods of use Dana-Farber Cancer Institute, Inc. (Boston, MA) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Olmutinib

Drugname Country Document Number Estimated Expiration Related US Patent
Olmutinib China CN107108649 2034-12-30 ⤷  Sign up for a Free Trial
Olmutinib European Patent Office EP3224257 2034-12-30 ⤷  Sign up for a Free Trial
Olmutinib Spain ES2759795 2034-12-30 ⤷  Sign up for a Free Trial
Olmutinib Japan JP2018502081 2034-12-30 ⤷  Sign up for a Free Trial
Olmutinib South Korea KR101803499 2034-12-30 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Boehringer Ingelheim
Harvard Business School
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.